Cohance Lifesciences Invests $18M in NJ Bio and Aruka Bio
Cohance Lifesciences Limited announced two strategic transactions to bolster its Antibody-drug Conjugate (ADC) strategy, involving a USD 13 million investment in NJ Bio and a USD 5 million controlling investment in Aruka Bio. These investments, funded by internal accruals, aim to deepen NJ Bio's integration with Cohance for customer-facing services and focus Aruka's proprietary pipeline development through partnerships. Cohance will increase its ownership in NJ Bio to 67.3% and gain a 65% direct ownership in Aruka Bio, which will become a direct subsidiary. These moves are expected to strengthen business performance and position Aruka's platform for future collaborations. Completion is anticipated by the end of September 2026.
Key Highlights
- Cohance Lifesciences invests $18M in NJ Bio and Aruka Bio to advance ADC strategy.
- NJ Bio ownership increases to 67.3%, Aruka Bio becomes a direct subsidiary with 65% ownership.
- Transactions aim to integrate NJ Bio's services and develop Aruka's proprietary pipeline.
- Funding will come from internal accruals, with completion expected by September 2026.
- Strategic reorganisation provides clear focus for both NJ Bio and Aruka Bio.
Price Impact
More from COHANCE